Drug-mediated inhibition of CDK4/CDK6 activity

Stable Identifier
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Cyclin dependent kinases CDK4 and CDK6 regulate crucial steps in the G1 phase of the cell cycle that commit cells to transition to the S phase and ultimately divide. Many growth signaling pathways, frequently perturbed in cancer, converge on CDK4/CDK6 activation, thus driving cellular proliferation. This makes CDK4 and CDK6 promising targets for anti-cancer therapy. So far, three CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib, have been approved for clinical use and many others are at different stages of clinical testing. CDK4/6 inhibitors mainly have a cytostatic effect on tumor cells, but can also influence immune response to tumor by targeting immune system cells in the tumor microenvironment. While intact RB1, the main target of CDK4/6 during cell cycle progression, is in general considered to be a prerequisite for the success of CDK4/6-targeted anti-cancer therapy, the status of other, less explored CDK4/6 targets can also affect the treatment outcome. For review, please refer to Asghar et al. 2015, Klein et al. 2018, Álvarez-Fernández and Malumbres 2020, Petroni et al. 2020).

Literature References
PubMed ID Title Journal Year
25633797 The history and future of targeting cyclin-dependent kinases in cancer therapy

Witkiewicz, AK, Asghar, U, Turner, NC, Knudsen, ES

Nat Rev Drug Discov 2015
32346095 Immunomodulation by anticancer cell cycle inhibitors

Petroni, G, Formenti, SC, Chen-Kiang, S, Galluzzi, L

Nat Rev Immunol 2020
29731395 CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

Tap, WD, Davis, LE, Koff, A, Kovatcheva, M, Klein, ME

Cancer Cell 2018
32289274 Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

Alvarez-Fernández, M, Malumbres, M

Cancer Cell 2020
Orthologous Events
Cite Us!